In the past 25 years, the drug discovery research and development (R&D) model has undergone dramatic changes. The major drivers of this transformation have been discussed at length in the literature. Initially, large pharmaceutical companies tried to fill their pipelines through mergers, but this rarely increased the output of new molecular entities. On the contrary, these mergers frequently had a negative effect on research productivity. This wave of mergers of pharma companies was followed by closures of R&D centers worldwide. As pharmaceutical companies continue to explore new ways to supplement their internal pipeline, they have started to look at earlier stage assets generated by third parties. To support these activities, venture capital firms entered the fray, paving the way for a new era of transformation that is often referred to as open innovation (OI). In this article, we review how this OI model operates.
12th Asian Federation for Medicinal Chemistry（AFMC）International Medicinal Chemistry Symposium（AIMECS 2019）が、2019年9月8日（日）～11日（水）にわたり、トルコ共和国イスタンブールにて開催された。本会は、“New Avenues for Design and Development of Translational Medicine”の副題のもと、12題の基調講演、30題の一般口頭発表、および58題のポスター発表が行われた。本レポートでは、学会の様子と概要について紹介する。